Friday, April 11, 2014

PROactive partners with Linkcare for COPD active coaching clinical trial

Linkcare will provide PROActive with Telemonitoring Services, Activity Tracking and Electronic Clinical Research Forms (eCRF) to support clinical a trial on COPD activity coaching  

About PROactive

PROactive is a European project funded by the Innovative Medicines Initiative (IMI). 

Under this initiative, several partners or stakeholders can be assembled with the common goal of improving care for patients with chronic obstructive lung diseases.

Under the auspices of this European initiative, PROactive is designing a new way to assess the effect of treatments such as medicines, rehabilitation or surgery, with the goal of developing a tool that captures physical activity of COPD patients. 

PROactive Program

Chronic Obstructive Pulmonary Disease (COPD) is a treatable and preventable lung disease which affects an increasing number of people in Europe. Physical inactivity and its associated symptoms are key features of COPD which contribute to the progression of the disease.

The aim of the 5-year PROactive project (Physical Activity as a Crucial Patient Reported Outcome in COPD) is to develop and validate patient reported outcome (PRO) tools to investigate dimensions of physical activity that are judged as being essential by patients. Currently, the means of measuring the outcomes of physical activity are very generic and do not include the patients\' experiences of how the disease affects their daily lives. The inability of patients with COPD to participate in daily physical activities is an important consequence of COPD, thus representing a daily challenge to patients. Improvement of the ability to participate in physical activity with minimum symptoms is a very important patient-centred target for treatments and other interventions in COPD.

PROactive seeks to address this significant gap, through the development of PRO tools that capture patient daily physical activity in a way that maximally reflect COPD patient experiences in dimensions considered most relevant by the patient. This unique project will be completed in 2014. 

PROactive Consortium

Pharmaceutical companies: Chiesi, GSK - GlaxoSmithKline, Pfizer, Almirall, Novartis, AstraZeneca, UCB, Boheringer Ingelheim.
Academic Institutions: KU Leuven - Katholieke Universiteit Leuven (Netherlands), The University of Edinburgh (Scotland), Thorax – Research Center of Intensive & Emergency Thoracic Medicine (Greece), Royal Brompton & Harefield NHS Foundation Trust (United Kingdom), CREAL - Centre de Recerca en Epidemiologia Ambiental (Catalonia), Universität Zurich (Switzerland), University Medical Center Groningen (Denmark).
Patient OrganisationsAstma Fonds Longstichting (Netherlands),  British Lung Foundation (United Kingdom), ERS - European Respiratory Society (Switzerland)
Small and Medium Enterprise: Choice Healthcare Solutions (United Kingdom)

The IMI partnership

The Innovative Medicines Initiative (IMI) is a unique public-private partnership between the pharmaceutical industry represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Communities represented by the European Commission. The aim of IMI is to support the faster discovery and development of better medicines for patients and to enhance Europe's competitiveness by ensuring that its biopharmaceutical sector remains a dynamic high-technology sector.